Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Blood

Volumn 97, Issue 10, 2001, Pages 3197-3204

  Van Der Velden, Vincent H J ^a,b,c   Te Marvelde, Jeroen G ^a,b,c   Hoogeveen, Patricia G ^a,b,c   Bernstein, Irwin D ^a,b,c   Houtsmuller, Adriaan B ^a,b,c   Berger, Mark S ^a,b,c   Van Dongen, Jacques J M ^a,b,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL TRIAL; CONFOCAL LASER MICROSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PROTEIN BINDING; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MONOCYTE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035874504     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3197     Document Type: Article

References (28)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol. 1999;36:2-8.
3. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048-1053.
4. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521-534.
5. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72:314-321.
6. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem. 1999;274:11505-11512.
7. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999;29:3440-3449.
8. Hamann PR, Hinman LM, Hallet WA, et al. Anti-CD33 calicheamicin hybrid conjugates for the treatment of acute myelogenous leukemia [abstract]. Proc AACR. 1996;37:471.
9. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198-1201.
10. Nicolaou KC, Smith AL, Yue EW. Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci U S A. 1993;90:5881-5888.
11. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
12. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993;677:265-280.
13. Rovera G, Santoli D, Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci U S A. 1979;76:2779-2283.
14. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985;66:1384-1392.
15. Mooij P, Simons PJ, de Haan-Meulman M, de Wit HJ, Drexhage HA. Effect of thyroid hormones and other iodinated compounds on the transition of monocytes into veiled/denddtic cells: role of granulocyte-macrophage colony-stimulating factor, tumour-necrosis factor-alpha and interleukin-6. J Endocrinol. 1994;140:503-512.
16. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and rightangle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993;100:534-540.
17. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science. 1999;284:958-961.
18. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184:39-51.
19. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83:1760-1768.
20. Korth-Bradley JM, Dowell JA, Berger MS, Liu H, King SP. Assessment of the possible influence of patient demographics on the pharmacokinetics of a new antibody-chemotherapeutic agent for relapsed acute myelogenous leukemia [abstract]. Pharmacotherapy. 1999;10:1217.
21. van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992;52:89-94.
22. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
23. Caron PC, Co MS, Bull MK,Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992;52:6761-6767.
24. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
25. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res. 1998;4:1421-1428.
26. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
27. Matthews DC. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia. 1998;12:S33-S36.
28. Sievers EL, Larson RA, Estey E, et al. Comparison of the efficacy and safety of gemtuzumab ozogamicin in patients <60 and ≥-60 years of age with AML in first relapse [abstract]. Proc ASCO. 2000;19:8a.